Michael J. Dochniak (Alleamit, Co-founder)
Mr. Dochniak is a University of Wisconsin, River Falls graduate. Michael was a senior chemist/patent coordinator at the H.B. Fuller Company and is an inventor of fifteen (15) U.S. patents.
Born from the creative expression of patents, Michael has authored books on the impact of intellectual property on Artificial Intelligence, Alzheimer’s Disease, Autism Spectrum Disorders, and Climate Change. Additionally, he has documented healthcare worker efforts in the book “Missionary Sheroes of the 19th to 21st Centuries.”
In cancer research, Michael’s passion is to discover novel ways that the body’s natural immune system can fight cancer. Alleamit’s core value is to push the boundaries of adaptive immunity and assault the immune tolerance of malignant tumors.
Our cancer research mission is to evaluate the validity of the null hypothesis that states, “forced atopy does not inhibit metastatic cancer.” Michael believes that allergies can be natural cancer immunotherapy and has several open-access publications describing the untapped power of allergenic skin creams and allergenic vaccines as cancer immunotherapy.
Cancer can be deadly when the immune system is weak or inefficient, resulting in solid tumors that metastasize. An active and robust immune system is the body’s natural defense. Alleamit’s skin cream technology activates the body’s adaptive immune system to disrupt the solid-tumor microenvironment. The mechanism of action encompasses cross-reactivity, immune metabolic interference, and targeted degranulation.
Can an expanded immune system starve out solid tumors? Harnessing the natural power of the immune system requires science-based nutrition. At Alleamit, managing essential fatty acids, proteins, carbohydrates, vitamins, minerals, and hydration supports our unique cancer immunotherapy.
Alleamit is a micro-entity organization in Minnesota, USA. Our patented skin cream explores activating adaptive immunity to inhibit metastasis. Cancer therapy is unoccupied with “allergenic” skin cream products. Alleamit’s approach explores pioneering skin creams as an immuno-stimulant. Natural ingredients, ease of manufacture, user-friendly application, and antibody-generating characteristics combine to make it a revolutionary immuno-therapeutic.
At Alleamit, we recognize that controlled allergies formed by our skin cream are a relative contraindication in that the risks of complications from allergies often do not outweigh the life-threatening situation of a tumor(s) growing out of control and metastasizing.
Skin Cream technology
Scientific consensus asserts that allergies are a maladaptive immune response. At Alleamit, this much-maligned immune response is under investigation to inhibit cancer. Our patented skin cream uses specific allergens to activate the body's natural immune system to disrupt the cancer microenvironment. The vision is to create cancer therapy that is inherent and patient-friendly.
Skin Cream Technology
Viral infections are a natural and inevitable part of life. In healthy individuals, mortality increases when the body’s innate immune system quickly activates, creating a cytokine storm. A rapid and excessive release of cytokines into the bloodstream can cause acute respiratory distress syndrome and death. Allergies have a stabilizing effect on the immune system during acute infections. At Alleamit, our skin cream therapy is designed to collaborate with innate immunity to reduce the clinical impact of a cytokine storm.
Allergies are nature's immunotherapy, this mechanism of evolution is embraced and safely magnified with Alleamit’s skin cream technology.
Engender natural immunity to fight life-threatening diseases
Skin cream to fight metastatic cancer.
August 2023 - Alleamit, Inc. enters into an agreement with Marquee Equity to invite global financing entities for initial FDA clinical phases.
March 2023 - Minnesota, United States of America, 2023 -- Alleamit, Inc. (Alleamit), is focused on novel skin cream immunotherapeutic; received a Notice of Allowance for the patent application titled Topical Hyper-allergenic Composition And Method Of Treating Using The Same (U.S. Patent Application # 16/513,334). The Notice of Allowance concludes a thorough examination of the skin cream application to become a U.S. patent.
Ever wonder why allergies exist? The immune system is trying to protect you from harm. At Alleamit, research, and development leverage allergies to disrupt and attack the spread of cancer. Our skin cream stimulates the body’s immune response to fight tumors through cross-reactivity, immune metabolic interference, and targeted degranulation. If confirmed in clinical trials, the ability to harness the body’s natural immune system could bring significant cost benefits to patients. Michael J. Dochniak (co-founder) writes that our skin creams encompass pharmaceutical-grade components and FDA-approved allergenics. The technology has the potential to address an unmet medical need in oncology, improve the lives of patients, and bring significant value to shareholders.
The strategy is to deliver superior growth and shareholder return by bringing novel skin cream products to market through global partnering and commercialization efforts.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements include our expectations regarding pending litigation and other matters. These forward-looking statements are subject to some risks, uncertainties, and assumptions, including, among other things: our history of operating losses and future profit variability; the outcome of any pending litigation; our ability to complete research and further development of our skin cream candidates; the timing, cost, and uncertainty of obtaining regulatory approvals for our skin cream candidates; our ability to commercialize our skin cream candidates; dependence on royalties and grant revenue; our ability to implement our growth strategy; anticipate trends in our business; our limited product line and distribution channels; advances in technologies and development of new competitive products; and our ability to maintain effective internal control over financial reporting. Investors can consider statements that include the words: to; may; could; future; expectations; anticipate; projections; and similar expressions, as well as the negatives of those words or other comparable words, to be uncertain forward-looking statements. Placing undue reliance on any forward-looking statements could turn out to be incorrect. We undertake no obligation to update publicly or revise any forward-looking statements, whether because of new information, future events, or after the date of this report. Forward-looking events and circumstances discussed in this report may not occur; results could differ materially from those anticipated or implied in the forward-looking statements.
Michael J. Dochniak
Mr. Dochniak is a University of Wisconsin, River Falls graduate. Michael was a senior chemist/patent coordinator at the H.B. Fuller Company and an inventor of fifteen (15) U.S. patents.
Born from the creative expression of patents, Michael has authored books on the impact of intellectual property on Artificial Intelligence, Alzheimer's Disease, Autism Spectrum Disorders, and Climate Change. Additionally, he has documented healthcare worker efforts in the book Missionary Sheroes of the 19th to 21st Centuries.
Michael’s passion is discovering novel ways the body’s natural immune system can fight cancer. Alleamit’s core value is to push the boundaries of adaptive immunity and assault the immune tolerance of malignant tumors. The cancer research mission is to evaluate the validity of the null hypothesis; forced atopy does not inhibit metastatic cancer. Michael believes that allergies can be natural cancer therapy and has several open-access publications describing the untapped power of allergenic skin creams and vaccines.
When it comes to attempting to put an end to cancer, we must not abandon — or, more precisely, ignore — allergy-assisted cancer therapy. Destroying malignant tumors is difficult; the body can do it naturally.
Christian J. Glancey
Christian Glancey acquired an advanced degree in linguistics from Central India Institute, New Deli. Mr. Glancey has founded several companies in the United States of America and is a lifelong entrepreneur.
In cancer research, Christian authored a review paper titled “Cancer-related Innovation and U.S. Patent Applications.” Christian’s contribution to cancer research represents a bootstrapping mentality wherein scientific discovery has no boundaries.
Cherie A. Benson
Cherie Benson attended St. Olaf College, Minnesota (Biology, and Graduated Cum Laude.)
Ms. Benson was Chief Operating Officer at the University of Minnesota - Department of Neurosurgery and Operation Director for the University of Minnesota Physicians - Neurosciences and Surgical Practices.
Cherie has always been interested in what promotes health and dis-ease in the body. In the spirit of natural healing, she is a Certified Health Coach having extensive experience with herbs, essential oils, and nutrition.
In cancer research, Cherie has co-authored several medical papers on humoral immunotherapy and diet. Through an integrative and functional medicine approach, she believes that the immune system can and will heal the body.
Nonclinical Drug Development Consultant and Scientific Advisor
Richard Ridgewell, PhD
As Founder and Principal Consultant at Ridgewell Consulting, LLC, Dr. Ridgewell is responsible for guiding clients with strategic direction and development plan execution for the nonclinical aspects of drug development and translational medicine programs. He provides consultation focused on scientific and regulatory aspects of nonclinical drug development across the disciplines of pharmacology,
toxicology and drug metabolism, and pharmacokinetics. Dr. Ridgewell’s expertise includes the integration of nonclinical findings toward the prediction of human dose and exposure, efficacy, and safety toward successful regulatory submissions.
Before establishing Ridgewell Consulting, he held positions of increasing responsibility and influence over more than 28 years in Drug Discovery and Drug Development within the pharmaceutical industry in North America, including Upsher-Smith, Boehringer-Ingelheim, Pharmacia (Pfizer), 3M Pharmaceuticals and Bristol-Myers Squibb.
Dr. Ridgewell also gained direct contract research experience as a Research Director at Covance Laboratories. He has presented on
twelve drug discovery and development topics at scientific conferences, participated as an instructor in continuing education courses for pharmaceutical scientists, authored nine peer-reviewed publications, and co-authored a book chapter on drug-transporter interactions. He has established quality/GLP programs to ensure regulatory compliance of nonclinical programs, provided strategic planning and tactical execution for multiple drug discovery and nonclinical development programs, and participated as author and final reviewer/editor of IND and NDA submission documents.
Dr. Ridgewell holds a Bachelor’s degree in Chemistry and a Ph.D. in Medicinal Chemistry from the University of Minnesota.
Alleamit welcomes investors
Our strategic goals include broadening U.S. patent protection, procurement of evidence-based research, FDA approval, and negotiating licensing for worldwide distribution.
Alleamit’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the company’s pipeline through global partnering and commercialization efforts.
Our skin creams have the potential to address a large unmet medical need, improve the lives of a great number of individuals, and bring significant value to Alleamit’s shareholders.
For more information on how to invest, please contact:
Investor Relations Contact
Phone: (213) 600-7272